What is H.U. Group Holdings, Inc. (MRCHF)?

H.U. Group Holdings, Inc. (MRCHF) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of MRCHF?

The current price of MRCHF is $24.50. Prices are updated in real time on Stocks360.

What is MRCHF's price-to-earnings (PE) ratio?

MRCHF's trailing twelve-month PE ratio is 22.81, based on current price and earnings per share data available on Stocks360.

What is MRCHF's market capitalization?

MRCHF's market capitalization is $1,349,234,943.00, placing it in the small-cap tier.

Does MRCHF pay a dividend?

Yes. MRCHF has a trailing twelve-month dividend yield of 0.03%. Dividend data is sourced from financial market providers and displayed on Stocks360.

H.U. Group Holdings, Inc. (MRCHF)

Stock analysis · OTC · Healthcare · Medical - Diagnostics & Research

$24.50

Market Cap

$1.35B

PE (TTM)

22.81

EPS (TTM)

N/A

Dividend Yield

3.18%

Beta

0.29

Day Range

$24.50 – $24.50

52-wk Range

$18.60 – $25.01

Avg Volume

N/A

Volume

100.00

H.U. Group Holdings, Inc. (MRCHF) is a publicly traded company in the Healthcare sector. Latest price: $24.50. Market cap $1.35B. Trailing PE 22.81. Dividend yield 3.18%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 10 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $24.50 2026-10-30 · $24.50 (+0.00%)

Earnings

Most Recent

Aug 12, 2026

EPS $0.17 vs est. $0.10

Beat by $0.07

Next Earnings

Nov 11, 2026

EPS estimate $0.15

Proprietary Signals

Signal snapshot temporarily unavailable.

About H.U. Group Holdings, Inc.

H.U. Group Holdings, Inc., primarily operates in Japan, offering a wide array of laboratory testing products and services through its subsidiaries. Its service portfolio encompasses diagnostic testing for healthcare facilities, self-medication support, analytical services for the food, environmental, and cosmetic sectors, and testing provisions for corporate health insurance associations. The group also engages in the research, development, manufacturing, and sale of in vitro diagnostic (IVD) equipment. This portfolio features the LUMIPULSE, an automated chemiluminescent enzyme immunoassay system delivering reagents for detecting infectious diseases, various cancers, and lifestyle-related conditions to both medical institutions and diagnostic centers. They also produce ESPRINE, a line of rapid diagnostic kits for conditions like influenza, hepatitis B, and the novel coronavirus. Furthermore, the company supplies essential ingredients for pharmaceutical test drugs. The group further extends its offerings to include administrative support for hospitals, providing aid for surgical and endoscope room operations, medical equipment inspection and maintenance, and in-hospital logistics a…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	22.81×
P/S (TTM)	0.87×
P/B	1.62×
PEG	0.04×
P/FCF (TTM)	10.23×
EV / EBITDA	6.93×
EV / Sales	0.94×
Earnings Yield	4.41%
Free Cash Flow Yield	9.77%
Dividend Yield	3.18%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$232.52B
Revenue (TTM)	$248.56B
Net Income (TTM)	$9.55B
Free Cash Flow (TTM)	$19.62B
Net Debt	$15.76B
Working Capital	$54.77B
Gross Margin	28.91%
Operating Margin	2.42%
Net Margin	3.86%
Return on Equity	7.08%
Return on Invested Capital	2.25%